In recognition of the desire by sponsors and advertisers of therapeutic goods to contribute to the dissemination of the Government's public health messaging about COVID-19 testing, the TGA has issued a permission under section 42DK of the Act, which allows advertisers of certain therapeutic goods included on the ARTG (including listed medicines) to use specific statements that expressly refer to COVID-19 in the context of advising individuals to follow health advice about COVID-19 testing.
The TGA has provided specific wording for the permitted Covid-19 testing statements and has also provided other general cautions about remaining in advertising compliance.
The use of the statements is voluntary and the permission ceases on 31 December 2022.
General statements without reference to COVID-19 may also be used and examples are provided in the new guidance.
Please read today’s technical alert for more information,